Summary of clinical trial barriers deemed by all stakeholder groups as opportunities for the most impact if addressed (not in rank order)
| 1 | Harmonization of demographic terminology and data collection is needed. |
| 2 | Engagement of LEEs from study inception to dissemination of results and through regulatory assessment is needed. |
| 3 | Implicit biases continue to impede patient enrollment. |
| 4 | IRBs need to uphold the justice principle, which is part of their mandate. |
| 5 | Eligibility criteria should not exclude important groups. |
| 6 | DCT options can improve inclusion. |
| 7 | Limited access to trial information. |
| 8 | Community physicians often are not engaged in the clinical trial ecosystem. |
| 1 | Harmonization of demographic terminology and data collection is needed. |
| 2 | Engagement of LEEs from study inception to dissemination of results and through regulatory assessment is needed. |
| 3 | Implicit biases continue to impede patient enrollment. |
| 4 | IRBs need to uphold the justice principle, which is part of their mandate. |
| 5 | Eligibility criteria should not exclude important groups. |
| 6 | DCT options can improve inclusion. |
| 7 | Limited access to trial information. |
| 8 | Community physicians often are not engaged in the clinical trial ecosystem. |